All Articles

One of the top questions posed to members of the leadership team at the Academy of Oncology Nurse & Patient Navigators (AONN+) is: “What is the caseload that oncology navigators should be carrying?” According to Danelle Johnston, MSN, RN, HON-ONN-CG, OCN, when the leadership team ultimately realized they did not have a good answer to that question, they identified the need for a navigation acuity tool.

The field of cardio-oncology is not about cancer of the heart, but rather the combined effect that different risk factors—particularly patient risk factors, cancer risk factors, and risk factors associated with cancer therapies—have on the heart.

Several years ago, the Academy of Oncology Nurse & Patient Navigators (AONN+) unveiled 35 evidence-based oncology navigation metrics developed in response to a void in the literature measuring the programmatic success of navigation programs.

Understanding the functions of different tissues in the body is key to understanding genetics and genomics.

Meet Dolores and Zhonnet. Between them, they have over 30 years of expertise working as patient navigators for underserved female cancer survivors in an urban setting. This is their story.

The COVID-19 pandemic will have far-reaching economic implications in the United States and abroad for the foreseeable future. During this session Murray Aitken, MBA, Director, IQVIA Institute, presented emerging data regarding some of the ways in which the pandemic is affecting the US economy.

Burt Zweigenhaft, PhD, D.Litt, Founder, Association for Value-Based Cancer Care, moderated a panel session in which 3 experts from the independent actuarial firm, Milliman, discussed recent data showing the ways in which the COVID-19 pandemic may affect the future of healthcare.

Lymphomas are a heterogeneous group of malignancies that are associated with substantial morbidity and mortality. Although standard chemoimmunotherapy regimens lead to durable remissions in a substantial proportion of patients, many individuals will relapse and develop refractory disease. Therefore, a clear need exists for the development of novel therapies that are designed to treat relapsed/refractory B-cell malignancies.

The development and utilization of novel therapies, including small-molecule agents, have undoubtedly altered the treatment landscape for many indolent non-Hodgkin B-cell malignancies in the frontline and relapsed/ refractory settings. The availability of such agents as Bruton tyrosine kinase, BCL2, and phosphoinositide 3-kinase (PI3K) inhibitors addresses an unmet need among oncologists and advanced practice providers (APPs) who are seeking additional therapeutic options for their patients, particularly those with relapsed/refractory disease.